Tagrisso is an anticancer medicine that is used in the treatment of non-small cell lung cancer.
This remedy contains Osimertinib, a substance that blocks the function of EGFR, a receptor for cancer cells that controls their growth and multiplication. In this way, the tumor cells fail to develop properly and the rate of cancer development decreases, improving the outcome of other treatments, such as chemotherapy.
Tagrisso is produced by AstraZeneca laboratories and can be purchased from prescription pharmacies in the form of 40- or 80-mg tablets.
Price
Although this drug has already been approved by Anvisa in Brazil, it is still not being marketed.
What is it for
Tagrisso is indicated for the treatment of adults with locally advanced non-small cell lung cancer or with T790M positive mutation metastases in the EGFR receptor gene.
How to use
Treatment with this medicine should always be directed by the oncologist, according to the degree of cancer development.
However, the recommended dose is 1 tablet of 80 mg or 2 of 40 mg once daily.
Possible side effects
The use of Tagrisso may cause some side effects such as diarrhea, stomach pain, urticaria and itching of the skin and changes in blood test, especially in the number of platelets, leukocytes and neutrophils.
Who should not use
Tagrisso should not be used by pregnant or nursing women as well as by people who are allergic to any of the ingredients in the formula. In addition, St. John's wort should not be taken during treatment with this medicine.
